Saturday 17 October 2026
Export PMCB’s income statement to Excel — free account
Nuvilex Inc.
PMCB Healthcare Biotechnology
In the quarter to July 2026, EPS grew 56.1% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.34
0.02
−5.56%
Follow PMCB
| Apr '26 | Apr '25 | Apr '24 | Apr '23 | Apr '22 | Apr '21 | Apr '20 | Apr '19 | Apr '18 | Apr '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
45.28 | 7.68 | 6.80 | 116.17 | 121.37 | 3.14 | 1.01 | 0.88 | 1.99 | 6.10 |
Net Debt/EBITDA |
5.41 | 3.54 | 5.89 | 10.54 | 19.44 | 0.61 | 0.21 | 0.13 | 0.15 | 0.78 |
Debt/Assets |
0.00% | 0.05% | 0.00% | 0.00% | 0.00% | 0.00% | 1.22% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.22 | (0.13) | 0.12 | 0.88 | 0.97 | 0.94 | 0.61 | 0.71 | 0.74 | 0.75 |
Interest Coverage |
— | — | — | (3.33) | (8,784.00) | (1,207.67) | (7,652.80) | — | — | (2,961.40) |
| (54.48%) | 58.74% | (34.36%) | (5.31%) | (8.78%) | (60.35%) | (75.57%) | (75.26%) | (98.57%) | (60.83%) | |
| (45.54%) | 40.60% | (25.89%) | (5.27%) | (8.65%) | (52.34%) | (64.05%) | (66.70%) | (90.57%) | (56.15%) | |
ROIC |
0.00% | (7.52%) | 0.00% | (86.76%) | (60.74%) | (50.57%) | (56.02%) | (56.65%) | (92.66%) | (60.05%) |
Return on Tangible Assets |
(63.42%) | 120.05% | (40.07%) | (6.39%) | (5.00%) | (229.05%) | (61,724.19%) | 4,544.36% | (1,067.50%) | (150.21%) |
Average Days of Receivables |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.03 | 0.03 | 0.05 | 0.04 | 0.48 | 0.58 | 0.61 | 0.55 | 0.41 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.61) | (0.41) | (0.22) | (0.19) | (0.27) | (2.30) | (2.59) | (3.74) | (7.49) | (5.64) |
Cash per Share |
4.43 | 2.12 | 5.24 | 3.49 | 5.50 | 1.52 | 0.99 | 0.67 | 1.56 | 5.85 |
Shareholders Equity per Share |
3.97 | 7.08 | 2.89 | 3.73 | 5.79 | 4.61 | 5.63 | 6.54 | 8.51 | 13.67 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.97 | 7.08 | 2.89 | 3.73 | 5.79 | 4.61 | 5.63 | 6.54 | 8.51 | 13.67 |
Free Cash Flow |
(5.15) | (2.98) | (2.15) | (3.79) | (4.12) | (3.33) | (2.34) | (2.88) | (5.08) | (3.34) |
Working Capital |
36.59 | 19.46 | 43.02 | 67.56 | 84.79 | 1.55 | 0.01 | (0.09) | 0.64 | 2.96 |
Net Current Asset Value |
23.96 | 19.10 | 18.18 | 67.56 | 84.79 | 1.55 | (0.04) | (0.09) | 0.64 | 2.96 |
| Other line items | ||||||||||
Quick Ratio |
45.16 | 6.60 | 6.76 | 115.99 | 121.24 | 3.04 | 0.87 | 0.69 | 1.65 | 5.97 |
Cash ROIC |
(7.32%) | (4.42%) | (2.76%) | (2.70%) | (2.35%) | (37.50%) | (38.59%) | (51.81%) | (74.39%) | (28.91%) |
Accounts Receivable Turnover |
0.00 | — | — | — | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.61) | (0.41) | (0.22) | (0.19) | (0.27) | (2.30) | (2.59) | (3.74) | (7.49) | (5.64) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
1.97 | — | — | — | — | — | — | — | — | — |
Average Payables |
0.34 | 0.39 | 0.26 | 0.17 | 0.19 | 0.18 | 0.15 | 0.24 | 0.36 | 0.35 |
Average Assets |
50.96 | 57.54 | 66.59 | 81.95 | 49.01 | 6.79 | 5.97 | 6.10 | 7.54 | 7.91 |
Average Common Equity |
42.59 | 39.77 | 50.17 | 81.31 | 48.30 | 5.88 | 5.06 | 5.40 | 6.93 | 7.30 |
Columns are period end dates · fundamentals updated 2 Oct 2026